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Abstract
Rationale, aims and objective: Cross‐country comparisons of cystic fibrosis (CF)
outcomes can potentially identify variation in care but are dependent on data quality.
An important assumption is that the UK annual review FEV1 is only collected during
periods of clinical stability. If this assumption does not hold, results of FEV1
comparisons may be biased in favour of registries with encounter‐based FEV1. We
aimed to test the assumption that CF annual reviews in the UK are only performed
during periods of clinical stability.
Method: Prospective encounter‐based data collected in Sheffield (n = 174) was used
to establish whether annual review FEV1 were always collected during periods of
clinical stability and to determine the group‐level discrepancy between annual review
vs best FEV1. We then went on to quantify the group‐level discrepancy between
annual review and best annual FEV1 readings within the UK registry (n = 2995) to
determine if the differences observed in Sheffield also apply to the wider UK data.
Results: Sheffield results showed a group‐level discrepancy between best and annual
review FEV1 of −2.5% (95% CI −3.95% to −1.2%) for annual reviews performed during
periods of clinical stability (n = 50). The group‐level discrepancy is larger at −8.0%
(95% CI −11.2% to −4.9%) among annual reviews performed during periods of clinical
instability (n = 13). Therefore, the magnitude of this group‐level discrepancy is a
surrogate for the proportion of clinically stable annual reviews—smaller discrepancy
indicates a higher proportion of clinically stable annual reviews and vice versa.
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The overall group‐level discrepancy in theUK registry (−5.6%, 95%CI −5.9 to −5.4%)was
similar to Sheffield (−6.1%, 95%CI −7.1 to −5.1%). Around 20% of the clinician reviewed,
annual reviews in Sheffield were performed during periods of clinically instability.
Conclusions: Annual review FEV1 underestimates lung health of adults with CF in
the UK and may bias cross‐country comparisons.
KEYWORDS
clinical epidemiology, cystic fibrosis, respiratory measurement
1 | INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive genetic condition which
affects multiple organs, in particular the lungs (resulting in recurrent
infections and respiratory failure) and the gastrointestinal tract
(resulting in malabsorption of fat and poor growth).1 Median predicted
survival has improved to over 40 years,2 likely because of a combina-
tion of factors including better early nutritional supplementation,
availability of more efficacious treatment options, and better quality
of care. Cross‐country comparisons can contribute to better quality
of care. For example, comparisons of nutritional outcomes and survival
between the Boston and Toronto CF centres in the 1980s identified
the benefits of aggressive nutritional support,3 which led to a unified
dietary approach for people with CF globally.4
Cross‐country CF registry comparison is now an increasingly com-
mon method used to identify variation in care and opportunities for
system improvement. Examples include the US‐Australia, US‐Canada,
and US‐UK comparisons.5-7 Forced expiratory volume in 1 second
(FEV1) is an important indicator of lung health among people with
CF and has been used an outcome measure in some of the cross‐
country comparisons. The recent US‐UK FEV1 comparison using
2010 dataset found superior FEV1 in the United States, especially
among those aged 6 to 25 years.7 Higher prescription of inhaled
mucolytics among US children was suggested by the investigators as
one of the reasons for this difference, although FEV1 differences actu-
ally persisted across all levels of treatments.7,8
Higher FEV1 is desirable because it is strongly associated with
better survival.6 Yet people with CF in the UK were significantly older
than the United States,7 which suggest that people in the United
Kingdom are living longer and have better outcomes. The “pyramid
of investigation” provides a systematic approach to understand this
apparent paradox and proposes data review as the first step.9
In 2010, the US registry collected encounter‐based FEV1 whereas
the UK registry only collected annual review FEV1. The US‐UK com-
parison used a matching algorithm taking into account seasonality of
the UK data to select one FEV1 reading from each US study subject.
7
Only clinically stable FEV1 from the United States were matched,
because of the assumption that the UK annual review FEV1 was
always collected “when subjects are well.”7 This assumption has never
been formally tested.
We investigated this issue by using prospective Sheffield Adult CF
Centre encounter‐based FEV1 data to establish whether annual
review FEV1 were always collected during periods of clinical stability.
We then went on to repeat our analysis using data from the UK CF
registry to determine if the Sheffield findings also apply UK‐wide.
2 | METHODS AND MATERIALS
Encounter‐based FEV1 data were prospectively collected in the Shef-
field Adult CF centre between 1 January and 31 December 2016 from
every adult who contributed data to the UK CF registry, excluding
those who had lung transplantation (n = 7) or on ivacaftor (n = 13).
Annual reviews were performed according to usual practice. In addi-
tion, clinicians' opinion of health status and Fuchs' criteria10 were
recorded during every encounter involving clinician review, including
outpatient clinics, ward reviews, and home visits. FEV1 readings were
deemed to be taken in a period of clinical stability if there was no
exacerbation, no requirement for intravenous antibiotics, and ≤3
Fuchs' symptoms present. Every annual review FEV1 was matched
to another clinically stable FEV1 that was closest to the annual review.
Mean paired difference and paired t test P‐value were calculated.
Non‐parametric comparisons were also performed to check the
robustness of the results.
The UK registry has no “stable FEV1” data but collects best FEV1
data since 2012 for the European registry.11 We therefore quantified
the group‐level discrepancy between best FEV1 and annual review
FEV1 in both Sheffield 2016 (best FEV1 data in Sheffield represent
the highest FEV1 reading between 1 January and 31 December
2016) and the UK registry 2014 datasets among people aged
≥16 years to determine if the differences observed in Sheffield also
apply UK‐wide.
The UK registry data were collected during annual reviews
between 1 January and 31 December 2014. The best FEV1 data in
the UK registry represent the highest FEV1 reading in the 1‐year
period prior to the date of annual review (ie if a person had annual
review on 1 July 2014, the highest FEV1 reading between 1 July
2013 and 1 July 2014 should be that person's “best FEV1” for 2014).
People who had lung transplantation (n = 330) or on ivacaftor (has
transformative effect on lung health but unavailable commercially in
2010,12 n = 281) in the UK registry were excluded. People attending
the adult Sheffield CF centre were also excluded to avoid duplicate
analysis of the same cohort.
All analyses were performed by using SPSS v22 (IBM Corp,
Armonk, NY, USA). Where statistical tests were performed, a P‐value
<.05 was considered to be statistically significant. Regulatory approval
for the analysis of prospective Sheffield data was granted by the
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National Health Service (NHS) Health Research Authority (IRAS
number 210313). National Health Service research ethics approval
(Huntingdon Research Ethics Committee 07/Q0104/2) was granted
for the UK CF Registry. Under the terms of the NHS ethics approval,
the UK CF Trust steering committee approved the use of anonymized
data for this analysis.
3 | RESULTS
A total of 174 adults were included for Sheffield analysis and 2995
adults for the UK CF registry analysis. Adults with and without best
FEV1 data in the UK CF registry shared similar clinical characteristics
(see Table 1).
There was significant group‐level differences between annual
review vs matched clinically stable FEV1 in Sheffield (mean −2.9%,
95% CI −3.8% to −1.9%), with similar differences among those with
paired readings within 30 days or >30 days apart. Not every episode
of clinical instability was accompanied by acute FEV1 decline, but var-
iability in FEV1 measurements meant that best FEV1 would tend to
exceed annual review FEV1 even when annual review was performed
during clinical stability. Sheffield results suggested a group‐level dis-
crepancy between best and annual review FEV1 of −2.5% (95% CI
−3.9% to −1.2%) for all annual reviews performed during periods of
stability (see Table 2). For all annual reviews performed during periods
of clinically instability, the group‐level discrepancy was larger at −8.0%
(95% CI −11.2% to −4.9%). In Sheffield, whereby 20% of the clinician
reviewed annual reviews were performed during periods of clinical
instability, the overall group‐level discrepancy between best and
annual review FEV1 was −6.1% (95% CI −7.5 to −5.1%).
A similar overall group‐level discrepancy of −5.6% (95% CI −5.9%
to −5.4%) was observed in the UK registry, suggesting that the propor-
tion of annual reviews performed during periods of clinical instability
around the UK was similar to Sheffield. This discrepancy was larger
among younger adults, similar to the pattern of FEV1 discrepancy
observed in the US‐UK comparison.7 Similar results were obtained
with non‐parametric comparisons (see Table 3), suggesting that our
estimates are robust.
4 | DISCUSSION
This is the first study to empirically demonstrate that annual review
FEV1 in the United Kingdom were not always collected during periods
of clinical stability. We found that the magnitude of group‐level dis-
crepancy between best and annual review FEV1 was larger for annual
reviews performed during periods of clinical instability, compared with
annual reviews performed during periods of stability. Therefore, the
magnitude of this group‐level discrepancy is a surrogate for the pro-
portion of clinically stable annual reviews—smaller discrepancy indi-
cates a higher proportion of annual review performed during periods
of stability and vice versa. Our results suggest that around 20% of
all annual reviews in the United Kingdom may be performed during
periods of clinical instability and that annual review FEV1 in the UK
registry underestimated lung health of adults with CF at a group level
by 2% to 4% in comparison to clinically stable FEV1.
This may bias the US‐UK FEV1 comparison against the UK,
because FEV1 when stable was the intended comparison metric in that
analysis. %FEV1 in our analysis was calculated by using Knudson equa-
tion but similar results would be obtained with GLI equation because
paired difference between 2 FEV1 readings was calculated.
13 Our
analysis was restricted among adults due to data availability in Shef-
field. Although most of the US‐UK FEV1 differences were among
younger people, the lack of differences among older adults does not
exclude the possibility that lung health at a group level in the United
Kingdom was being under‐estimated.
Our analysis cannot conclusively prove that the US‐UK FEV1
comparison was biased because some “clinically unstable” FEV1 in
the United States may be mislabelled as “clinically stable.” However,
we speculate that under‐estimation of lung health may be more of a
TABLE 1 Characteristics of adults with cystic fibrosis (CF) for Sheffield in 2016 and other CF centres in the 2014 UK CF registry dataset
Characteristics
2016 Prospective
Sheffield Data
(n = 174)
2014 UK CF Registry Data for Adults
With Both Best and Annual Review
FEV1 (n = 2995)
a
2014 UK CF Registry Data for Adults
Without Best FEV1 but Annual Review
FEV1 was Available (n = 1320)
a
Age in years, median, IQR 27 (21‐34) 28 (22‐35) 29 (23‐38)
Female, n, % 84 (48.3) 1336 (44.6) 620 (47.0)
Pancreatic insufficient,b n. % 134 (77.0) 2458 (82.6)c 1061 (80.9)d
CF related diabetes, n, % 49 (28.2) 979 (32.7) 445 (33.7)
BMI in kg/m2, median, IQR 23.4 (20.5‐26.1) 22.2 (20.2‐24.7) 21.9 (19.8‐24.4)
Annual review %FEV1,
e median, IQR 74.0 (55.0‐88.3) 66.1 (46.3‐84.7) 63.2 (44.2‐84.0)
Best %FEV1,
e median, IQR 83.0 (63.0‐93.0) 72.1 (52.9‐90.5) N/A
aAdults receiving care at the Sheffield Adult CF Centre were excluded from this analysis to avoid duplicate analysis of the same cohort. Among 4315 UK CF
registry adults with annual review FEV1 data in 2014, best FEV1 data were available for 2995 adults (69.4%). From 2012 onwards, the UK CF registry col-
lects the best FEV1 data because these data are required by the European CF registry.
bData for pancreatic replacement therapy (PERT) use were obtained. People on PERT were considered “pancreatic insufficient.” People not on PERT were
considered “pancreatic sufficient.” PERT use documented as “unknown” is considered as missing data.
cPancreatic status was missing for 21 (0.7%) of the adults with best FEV1 data in the UK CF registry.
dPancreatic status was missing for 8 (0.6%) of the adults without best FEV1 data in the UK CF registry.
e% predicted FEV1 was calculated with Knudson equation. For reference, see Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal
maximal expiratory flow‐volume curve with growth and aging. Am. Rev. Respir. Dis. 1983; 127: 725–34.
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problem with the UK data entry system, which does not have encoun-
ter‐based FEV1 data. Data are typically only entered once annually in
the UK with a mid‐January deadline to complete data entry for pre-
ceding year, yet annual reviews are staggered throughout the year
due to capacity issues. Around 40% of annual reviews are performed
during the final quarter of the year,7 when exacerbation risks are
higher.14 If people were unwell when they turn up for annual reviews
in the final quarter of the year, the choice would be between complet-
ing the annual review anyway or risk missing out on data entirely. Data
are entered throughout the year in the United States with no risk of
missing data when people turn up unwell for a particular clinical
encounter. A previous audit in 2012 also found that data included in
the US registry were highly accurate.15 Indeed, the distribution of
stable FEV1 data in the US registry (spread evenly throughout the
calendar year) is clearly different from the distribution of annual
review FEV1 data in the UK registry (clear seasonality with higher pro-
portion of data entered in the final quarter of the year),7 suggesting
inherent differences between these 2 metrics. In addition, our analysis
demonstrated that the magnitude of group‐level discrepancy between
best and annual review FEV1 was larger among younger compared
with older adults, which suggests that the bias from annual review
FEV1 was greater among younger adults. This correlates with the
FEV1 differences by age as observed in the US‐UK FEV1 comparison.
Of note, results of other cross‐country comparisons also provide
circumstantial evidence that annual FEV1 data may be under‐estimat-
ing lung health of people with CF in comparison to encounter‐based
FEV1 data. The 2003 US‐Australia comparison found greater height
and weight percentiles among Australian children (suggesting better
TABLE 2 Summary of parametric FEV1 comparisons for the 2016 Sheffield prospectively collected data and the 2014 UK CF registry dataset
Annual Review % FEV1 vs Matched Clinically
Stable % FEV1
Annual Review % FEV1
Mean (95% CI)
Matched Clinically Stable %
FEV1 Mean (95% CI)
Paired Mean Difference in
% FEV1 (95% CI)
Paired t Test
P‐Value
For the Sheffield cohort in 2016 (n = 173)a 71.4 (68.1 to 74.7) 74.3 (71.0 to 77.5) −2.9 (−3.8 to −1.9) <.001
Paired FEV1 readings within 30 days
(n = 56)
69.5 (63.9 to 75.0) 72.6 (67.0 to 78.2) −3.2 (−4.3 to −2.0) <.001
Paired FEV1 readings >30 days apart
(n = 117)
72.4 (68.2 to 76.5) 75.1 (71.1 to 79.1) −2.7 (−4.0 to −1.4) <.001
Annual review documented as clinically
unstableb (n = 13)
68.8 (54.9 to 82.6) 73.1 (58.7 to 87.4) −4.3 (−8.2 to −0.4) .033
Status of annual review unknownc (n = 110) 69.3 (65.4 to 73.1) 73.5 (69.8 to 77.2) −4.2 (−5.5 to −3.0) <.001
Annual review documented as clinically
stabled (n = 50)
76.8 (69.9 to 83.8) 76.3 (69.2 to 83.5) 0.5 (−0.5 to 1.6) .329
Annual Review % FEV1 vs Best Annual % FEV1 Annual Review % FEV1
Mean (95% CI)
Best Annual % FEV1 Mean
(95% CI)
Paired Mean Difference in %
FEV1 (95% CI)
Paired t Test
P‐Value
For the Sheffield cohort in 2016 (n = 174) 71.2 (67.8 to 74.5) 77.2 (74.0 to 80.4) −6.1 (−7.1 to −5.1) <.001
Annual review documented as clinically
unstableb (n = 13)
68.8 (54.9 to 82.6) 76.8 (62.6 to 90.9) −8.0 (−11.2 to −4.9) <.001
Status of annual review unknownc (n = 111) 68.9 (65.0 to 72.8) 76.3 (72.5 to 80.1) −7.4 (−8.7 to −6.1) <.001
Annual review documented as clinically
stabled (n = 50)
76.8 (69.9 to 83.8) 79.4 (72.7 to 86.0) −2.5 (−3.9 to −1.2) <.001
For the UK CF registry dataset in 2014
(n = 2995)e
66.0 (65.1 to 66.9) 71.7 (70.8 to 72.5) −5.6 (−5.9 to −5.4) <.001
16‐17 yearsf (n = 44) 81.2 (73.1 to 89.3) 88.0 (80.3 to 95.7) −6.8 (−9.4 to −4.3) <.001
18‐21 yearsf (n = 578) 73.4 (71.4 to 75.4) 80.0 (78.1 to 81.9) −6.6 (−7.3 to −5.9) <.001
22‐25 yearsf (n = 582) 68.0 (66.0 to 69.9) 74.4 (72.5 to 76.3) −6.5 (−7.1 to −5.8) <.001
26‐29 yearsf (n = 495) 62.7 (60.5 to 64.9) 68.0 (65.8 to 70.2) −5.3 (−5.8 to −4.7) <.001
30‐33 yearsf (n = 412) 62.0 (59.7 to 64.4) 66.9 (64.6 to 69.2) −4.9 (−5.4 to −4.3) <.001
34‐37 yearsf (n = 287) 62.3 (59.3 to 65.2) 67.5 (64.7 to 70.4) −5.3 (−6.0 to −4.5) <.001
38‐41 yearsf (n = 169) 66.1 (62.2 to 70.0) 71.1 (67.3 to 74.8) −5.0 (−6.0 to −4.0) <.001
42‐45 yearsf (n = 148) 61.4 (57.6 to 65.3) 66.0 (62.3 to 69.8) −4.6 (−5.6 to −3.5) <.001
46‐49 yearsf (n = 111) 64.3 (58.9 to 69.7) 68.9 (63.6 to 74.3) −4.6 (−6.3 to −3.0) <.001
≥50 yearsf (n = 169) 61.4 (57.4 to 65.4) 66.1 (62.2 to 70.0) −4.7 (−5.5 to −3.9) <.001
aOne person had no clinically stable FEV1 in 2016.
bAn annual review was deemed “clinically unstable” if clinicians felt exacerbation was present, or if clinicians felt intravenous antibiotics was required, or if
≥4 Fuchs' symptoms were present.
cThe health status of an annual review status was “unknown” if the adult with CF was not formally reviewed by a CF clinician during the annual review.
Most annual reviews in Sheffield do not involve a formal clinical review.
dAn annual review was deemed “clinically stable” if clinicians felt there was no exacerbation, no requirement for intravenous antibiotics, and ≤3 Fuchs'
symptoms present.
eAmong 4315 UK CF registry adults (adults in Sheffield excluded) with annual review FEV1 data in 2014, best annual FEV1 data were available for 2995
adults (69.4%).
fThese are the same age ranges used in the US‐UK FEV1 comparison.
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nutritional outcomes), which is not surprising given that Australian
children were much more likely to be diagnosed after newborn screen-
ing (65.8%) compared with US children (7.2%).5 Australia also
delivered more aggressive treatment for pulmonary exacerbations,5
which contributes to better lung health.16-18 Despite the very strong
correlation between nutritional outcomes and lung health,19-21 FEV1
were actually similar between Australian and US children.5 In fact,
Australian children had significantly lower FEV1 after adjusting for
the mode of diagnosis.5 In 2003, the US registry started collecting
encounter‐based FEV1 data whilst the Australian registry was
collecting FEV1 data annually.
5 It may be that annual FEV1 in Australia
was under‐estimating the lung health of Australian children, which
could explain the disconnect between nutritional outcomes and lung
health observed in the US‐Australia comparison.
Differences in outcomes detected by registry comparisons attract
significant attention; hence, a rigorous process should be adopted to
TABLE 3 Summary of non‐parametric FEV1 comparison for the 2016 Sheffield prospectively collected data and the 2014 UK CF registry dataset
Annual Review % FEV1 vs Matched
Clinically Stable % FEV1
Annual Review %
FEV1 Median (IQR)
Matched Clinically Stable
% FEV1 Median (IQR)
Paired Median Differencea
in % FEV1 (95% CI)
Wilcoxon Signed
Rank Test P value
For the Sheffield cohort in 2016
(n = 173)b
74.0 (55.0 to 88.5) 80.0 (58.5 to 89.5) −3.0 (−4.0 to −2.0) <.001
Paired FEV1 readings within 30 days
(n = 56)
72.5 (55.8 to 85.0) 78.0 (59.5 to 87.0) −5.0 (−6.5 to −3.5) <.001
Paired FEV1 readings >30 days apart
(n = 117)
76.0 (55.0 to 90.0) 80.0 (57.0 to 91.0) −2.5 (−3.5 to −1.5) <.001
Annual review documented as
clinically unstablec (n = 13)
71.0 (49.5 to 91.0) 77.0 (53.5 to 92.0) −5.0 (−9.0 to 0.0) .041
Status of annual review unknownd
(n = 110)
73.5 (53.0 to 85.0) 78.0 (57.8 to 88.0) −4.0 (−5.5 to −3.0) <.001
Annual review documented as
clinically stablee (n = 50)
81.5 (59.0 to 92.3) 82.5 (61.8 to 94.0) 0.5 (−1.0 to 2.5) .371
Annual Review % FEV1 vs Best Annual
% FEV1
Annual Review % FEV1
Median (IQR)
Best Annual % FEV1
Median (IQR)
Paired Median Differencea in
% FEV1 (95% CI)
Wilcoxon Signed Rank
Test P value
For the Sheffield cohort in 2016
(n = 174)
74.0 (55.0 to 88.3) 83.0 (63.0 to 93.0) −6.5 (−7.5 to −6.0) <.001
Annual review documented as clinically
unstablec (n = 13)
71.0 (49.5 to 91.0) 79.0 (58.5 to 100.0) −8.0 (−11.0 to −4.5) .002
Status of annual review unknownd
(n = 111)
73.0 (53.0 to 85.0) 81.0 (62.0 to 91.0) −7.0 (−8.0 to −6.0) <.001
Annual review documented as clinically
stablee (n = 50)
81.5 (59.0 to 92.3) 84.5 (63.0 to 94.3) −5.5 (−8.0 to −3.5) <.001
For the UK CF registry dataset in 2014
(n = 2995)f
66.1 (46.3 to 84.7) 72.1 (52.9 to 90.5) −6.6 (−6.9 to −6.4) <.001
16‐17 yearsg (n = 44) 89.3 (59.3 to 102.8) 93.2 (67.6 to 105.8) −9.2 (−12.1 to −5.8) <.001
18‐21 yearsg (n = 578) 76.5 (56.8 to 91.5) 82.2 (65.9 to 96.8) −7.4 (−8.1 to −6.8) <.001
22‐25 yearsg (n = 582) 68.9 (49.9 to 85.7) 75.7 (58.2 to 91.9) −7.6 (−8.2 to −7.0) <.001
26‐29 yearsg (n = 495) 60.4 (43.6 to 80.5) 68.0 (48.9 to 87.0) −6.3 (−6.9 to −5.8) <.001
30‐33 yearsg (n = 412) 61.3 (41.3 to 80.7) 67.0 (46.6 to 85.1) −6.0 (−6.7 to −5.4) <.001
34‐37 yearsg (n = 287) 60.1 (42.2 to 80.0) 65.0 (49.3 to 83.8) −6.0 (−6.7 to −5.3) <.001
38‐41 yearsg (n = 169) 65.7 (45.5 to 85.3) 70.8 (53.6 to 89.5) −6.0 (−7.2 to −5.0) <.001
42‐45 yearsg (n = 148) 60.8 (42.4 to 79.6) 65.9 (51.4 to 83.7) −5.7 (−6.8 to −4.7) <.001
46‐49 yearsg (n = 111) 62.6 (38.9 to 85.4) 70.2 (47.0 to 90.1) −5.3 (−7.0 to −4.0) <.001
≥ 50 yearsg (n = 169) 56.9 (39.5 to 82.2) 61.9 (45.1 to 87.9) −5.9 (−6.8 to −5.2) <.001
aThe non‐parametric method used to estimate the population paired difference between 2 groups involves first calculating all n differences d1, d2, ..., dn. We
then calculate all possible n (n + 1)/2 averages of pairs of the differences (d1 + d2)/2, (d1 + d3)/2 etc. including (di + di)/2 for i = 1, 2, …, n, and then selecting
the median of the averages. This method can also be used to find confidence intervals for this median. For reference, see Campbell MJ, Gardner MJ. Cal-
culating confidence intervals for some non‐parametric analyses. Br Med J 1988; 296: 1454‐6.
bOne person had no clinically stable FEV1 in 2016.
cAn annual review was deemed “clinically unstable” if clinicians felt exacerbation was present, or if clinicians felt intravenous antibiotics was required, or if
≥4 Fuchs' symptoms were present.
dThe health status of an annual review status was “unknown” if the adult with CF was not formally reviewed by a CF clinician during the annual review.
Most annual reviews in Sheffield do not involve a formal clinical review.
eAn annual review was deemed “clinically stable” if clinicians felt there was no exacerbation, no requirement for intravenous antibiotics, and ≤3 Fuchs'
symptoms present.
fAmong 4315 UK CF registry adults (adults in Sheffield excluded) with annual review FEV1 data in 2014, best annual FEV1 data were available for 2995
adults (69.4%).
gThese are the same age ranges used in the US‐UK FEV1 comparison.
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interpret the results. The “pyramid of investigation” model advocates
an incremental approach to understand outcome variation, starting
with data review and only inferring differences in the quality of care
(eg mucolytic prescriptions) where data are robust. Attention should
be paid to differences in data collection systems because systematic
bias in data cannot be easily controlled with statistical methods, even
for objective outcomes, e.g. survival.22 Best FEV1 may be more reliable
than annual review FEV1 but may still under‐estimate lung health if
these data were only collected once a year, as suggested by the US‐
Australia comparison. Indeed, best FEV1 data are most robust if all
FEV1 readings are recorded in a single database, such that the highest
reading over a given time period can be automatically and accurately
identified. Harmonization of data collection system for CF registries
around the world using encounter‐based data entry would enable
more accurate cross‐country comparisons and also allow the use of
other potentially more sensitive metrics such as FEV1 variability for
comparison.23
Systematic data differences should be considered when analysing
data and interpreting results from cross‐country registry comparisons.
We have demonstrated that UK annual reviews are not always col-
lected during periods of clinical stability. This has potential impact on
comparisons with the US registry that collects encounter‐based FEV1.
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